Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
Calendar
–
View all events & presentations
Events.
Nov
09
2026
Virtual Event: PIK-201 Phase 2 Data in Advanced Endometrial Cancer
Oct
06
2026
Virtual KOL Event: Multi-Nodal Inhibition for the Treatment of Endometrial Cancer
Latest
–
View all news
News and updates.
Nov 09 2026
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
Confirmed Objective Response Rate (ORR) of 33% in efficacy-evaluable patients (12 of 36), and a disease control rate (DCR) of 83% Among patients with a PIK3CA mutation, the confirmed ORR was 44% (7 of 16) Preliminary Kaplan-Meier estimated median progression-free survival (mPFS) of 7.4 months, with
Read More
Nov 06 2026
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 6, 2026-- Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to
Read More
Nov 05 2026
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas --(BUSINESS WIRE)--Nov. 5, 2026-- Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth’s Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company’s common stock in connection with their
Read More
Nov 03 2026
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026 AUSTIN, Texas
Read More
Oct 27 2026
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro Dr. Schayowitz has led dozens of global development programs and led multiple registration programs through regulatory approval AUSTIN, Texas
Read More